Edgen Stock·Sep 24 2025, 03:54戻る
戻る
Merck Receives FDA Approval for Subcutaneous Keytruda
Edgen Stock·Sep 24 2025, 03:54
[1] Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff (https://finance.yahoo.com/m/cd506ba7-c40c-3fd ...)[2] As Exclusivity Loss Looms, Merck Wins Subcutaneous Approval for Keytruda - BioSpace (https://www.biospace.com/article/as-exclusivi ...)[3] Merck's Keytruda Qlex: A Strategic Leap in Competitive Differentiation and Oncology Market Expansion - AInvest (https://vertexaisearch.cloud.google.com/groun ...)